Related Experiment Video
Updated: Apr 29, 2026
04:44
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
22.1K
sCD126 as An Independent Prognostic Biomarker in Critical COVID-19
Giorgos Marinakis1, Eleni Karakike2, Panagiotis Koufargyris3
1Intensive Care Unit, Athens General Hospital "Korgialenio-Benakio", Athens, Greece.
Journal of Innate Immunity
|April 27, 2026
Summary
Soluble CD126 (sCD126) levels in critical COVID-19 patients treated with tocilizumab (TCZ) can predict outcomes. Higher sCD126 levels independently indicated a worse 28-day prognosis in this patient group.
Area of Science:
- Critical care medicine
- Immunology
- Pharmacology
Background:
- Biomarkers are needed to predict critical COVID-19 patient response to tocilizumab (TCZ).
- Serum levels of interleukin-6 (IL-6) and IL-6 soluble receptors were investigated in patients receiving TCZ.
Purpose of the Study:
- To identify biomarkers predicting the 28-day outcome in critical COVID-19 patients treated with TCZ.
- To determine a cut-off value for specific biomarkers associated with poor prognosis.
Main Methods:
- A prospective study measured serum IL-6, soluble CD126 (sCD126), and sgp130 in 127 critical COVID-19 patients within 24 hours of mechanical ventilation and before TCZ.
- Outcomes were assessed using the World Health Organization Clinical Progression Scale (WHO-CPS) at day 28.
Main Results:
- Elevated serum sCD126 levels (≥100 ng/mL) were independently associated with a worse outcome (WHO-CPS ≥6) at 28 days.
- The association showed an Odds Ratio of 2.42 (95% CI: 1.05-5.63, p=0.039).
Conclusions:
- Serum sCD126 is a predictor of the 28-day outcome in critical COVID-19 patients receiving TCZ.
- sCD126 may aid in stratifying patients for targeted therapies or closer monitoring.
